Company intelligence / Profile preview

TheraPei Pharmaceuticals

San Diego, California, USA

Ownership: Private
Development stage: Other

Overview

TheraPei Pharmaceuticals was a San Diego-based biotechnology company focused on developing novel therapeutics for metabolic diseases and oncology. Spun out of Sequenom in 2005, the company leveraged genomic insights to identify and develop small molecule candidates, most notably the brain-penetrant taxane TPI 287. TheraPei was acquired by Forbes Medi-Tech in 2006, and its pharmaceutical assets were subsequently sold to Transition Therapeutics in 2008. The company's lead programs targeted Type 2 diabetes and various cancers, with TPI 287 continuing development through several subsequent owners for indications like glioblastoma and neuroblastoma.

Therapeutic areas: OncologyEndocrinologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Sequenom

Beyond the preview

Go deeper on TheraPei Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TheraPei Pharmaceuticals.

Explore the full profile